Carl Gastanes, NP
Primary Care · New York, NYNPI 1821581141
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,669 of the $2,149 with a category attached, or 77.7%. 9 manufacturers reported payments, led by Livanova USA, Inc. at 38.2% of the total. Reporting peaked in 2024 at $904 and has fallen 97.5% since, to $22 in 2025.
Across 66 payments — averaging $32.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$821
- AbbVie$394
- Esperion Therapeutics, Inc.$296
- Amgen$210
- AstraZeneca$205
- Novo Nordisk$71
- plus $152 from 3 others
What the payments were for
- Travel & lodging$46622%
- Food & beverage$1,66978%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 4 | $821 |
| AbbVie | 20 | $394 |
| Esperion Therapeutics, Inc. | 5 | $296 |
| Amgen | 13 | $210 |
| AstraZeneca | 14 | $205 |
| Novo Nordisk | 4 | $71 |
| Novartis | 4 | $69 |
| Jazz Pharmaceuticals Inc. | 1 | $46 |
| Pyros Pharmaceuticals, Inc. | 1 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$821
- NEXLIZET$250
- NEXLETOL$250
How this compares
$2,149 in reported general payments places this provider in the 85th percentile of 239 primary care providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $86 |
| Naproxen | 17 | $32 |
| Azithromycin | 13 | $26 |
| Prednisone | 12 | $23 |
| Cyclobenzaprine Hcl | 21 | $16 |
Paid to pharmacies, not to this prescriber.
Other primary care in New York
- Dorothy KleinertNew York$27K
- Lisa PlanetaNew York$6K
- Erica StumpfNew York$4K
- Eunae KoNew York$4K
- Mona AboulnajaNew York$2K
- Kristl RamjattanNew York$2K
- Yan Fon MeiNew York$2K
- Villicent UyNew York$2K
- Kathryn DowlingNew York$2K
- Stephanie KhanForest Hills$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.